Quercetin

Quercetin

SCHEMBL288466

O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12.O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.92
KMT2A Q03164 11/20 0.92
CYP1A2 P05177 8/20 0.92
CYP3A4 P08684 8/20 0.92
KDM4E B2RXH2 8/20 0.92
HSD17B10 Q99714 8/20 0.92
MAPT P10636 8/20 0.92
CYP2C9 P11712 7/20 0.92
CYP1A1 P04798 7/20 0.92
CYP1B1 Q16678 7/20 0.92
XDH P47989 7/20 0.92
FTO Q9C0B1 7/20 0.92
RECQL P46063 7/20 0.92
ALOX15 P16050 6/20 0.92
ABCB1 P08183 6/20 0.92
APP P05067 6/20 0.92
TP53 P04637 5/20 0.92
IPMK Q8NFU5 5/20 0.92
IP6K2 Q9UHH9 5/20 0.92
BCHE P06276 5/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercetin SCHEMBL29351036 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL29723041 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL29353785 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL19723 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL118425 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL31507620 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL17629824 0.96 MEN1 (1.00) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL4815328 0.94 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL3786991 0.94 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4KDM4E
Quercetin SCHEMBL21590136 0.94 MEN1 (0.97) MEN1KMT2ACYP1A2CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022006187-A1 METHODS OF USING CANNABINOID COMPOSITIONS FOR INDUCING AND PROMOTING SLEEP NP PHARMA HOLDINGS, LLC (US) 2022-01-06 WO disclosed
US-20210401794-A1 Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep NP PHARMA HOLDINGS. LLC 2021-12-30 US disclosed
US-10758580-B2 Composition of sea buckthorn pulp oil and panax notoginseng saponins for treating osteoporotic fracture and/or osteoarthritis and uses thereof SHAANXI TIANKUI BIOMEDICINE TECHNOLOGY LIMITED COMPANY (CN) 2020-09-01 US disclosed
WO-2020102559-A1 A METHOD OF MAKING A FLAVONOID SOLUTION AND APPLICATIONS THEREOF FOR PLANT GROWTH PROMOTION, SEED COATING, PATHOGEN ELIMINATION, AND HERBICIDE STUNTING EFFECT REMOVAL WESTHUIZEN PIETER THERON VAN DER (ZA) 2020-05-22 WO disclosed
US-20200146287-A1 METHOD OF MAKING A FLAVONOID SOLUTION AND APPLICATIONS THEREOF FOR PLANT GROWTH PROMOTION, SEED COATING, PATHOGEN ELIMINATION, AND HERBICIDE STUNTING EFFECT REMOVAL THE BIO CONSULTING (PTY) LTD (ZA) 2020-05-14 US disclosed
WO-2018172942-A1 QUERCETIN NANOPARTICLES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2018-09-27 WO disclosed
US-20180161383-A1 NATURAL PHARMACEUTICAL COMPOSITION FOR TREATING MENOPAUSAL MENTAL DEPRESSION AND ATYPICAL DEPRESSIVE DISORDER AND APPLICATION THEREOF SHAANXI TIANKUI BIOMEDICINE TECH LIMITED COMPANY (CN) 2018-06-14 US disclosed
US-20180125907-A1 NATURAL PHARMACEUTICAL COMPOSITION FOR TREATING OSTEOPOROTIC FRACTURE AND/OR OSTEOARTHRITIS AND USE THEREOF ZHEJIANG INNOVATION WISDOM VALLEY TECHNOLOGY CO., LTD (CN) 2018-05-10 US disclosed
CN-106187972-A A kind of extraction kaempferol and method of Quercetin from Radix Hamamelidis Mollis 威海出入境检验检疫局检验检疫技术中心 2016-12-07 CN disclosed
CN-105176038-A Antibacterial and anti-aging plastic switch socket and preparation method thereof LU SIYE 2015-12-23 CN disclosed
EP-2427063-A1 WHOLE CEREAL FOOD PRODUCTS Planteriet ApS (DK) 2012-03-14 EP disclosed
US-20110112181-A1 POLYPHENOL COMPOUNDS WITH MODULATING NEUROTRANSMITTER RELEASE SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) 2011-05-12 US disclosed
EP-2258391-A1 Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids Stallergenes S.A. (FR) 2010-12-08 EP disclosed
WO-2010127912-A1 WHOLE CEREAL FOOD PRODUCTS PLANTERIET APS (DK) 2010-11-11 WO disclosed
WO-2010109256-A1 ENHANCED TREATMENT OF JOINT AND CONNECTIVE TISSUE DAMAGE GHISALBERTI CARLO (BR) 2010-09-30 WO disclosed
WO-2008111796-A1 POLYPHENOL COMPOUNDS WITH MODULATING NEUROTRANSMITTER RELEASE SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) 2008-09-18 WO disclosed
EP-1555870-A4 METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS SAMUEL ROBERTS NOBLE FOUND INC (US) 2006-11-02 EP disclosed
EP-1555870-A2 METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 2005-07-27 EP disclosed
WO-2004024079-A2 METHODS AND COMPOSITIONS FOR PRODUCTION OF FLAVONOID AND ISOFLAVONOID NUTRACEUTICALS THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 2004-03-25 WO disclosed
US-6030621-A Ginkgo biloba composition, method to prepare the same and uses thereof SPH XINGLING SCI. & TECH. PHARMACEUTICAL CO., LTD (CN) 2000-02-29 US disclosed